Taselisib


Taselisib is an experimental cancer drug in development by Roche. It is a small molecule inhibitor targeting the p110α protein product of the phosphoinositide 3-kinase gene, PIK3CA.
Taselisib is in phase III clinical trials for treatment of metastatic breast cancer and non-small cell lung cancer.